- Home
- SRTS vs NRXP Comparison
SRTS vs NRXP Comparison
Compare SRTS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- NRXP
- Stock Information
- Founded
- SRTS 2010
- NRXP 2015
- Country
- SRTS United States
- NRXP United States
- Employees
- SRTS N/A
- NRXP N/A
- Industry
- SRTS Medical/Dental Instruments
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- NRXP Health Care
- Exchange
- SRTS Nasdaq
- NRXP Nasdaq
- Market Cap
- SRTS 51.8M
- NRXP 58.5M
- IPO Year
- SRTS 2016
- NRXP N/A
- Fundamental
- Price
- SRTS $3.45
- NRXP $3.58
- Analyst Decision
- SRTS Strong Buy
- NRXP Strong Buy
- Analyst Count
- SRTS 3
- NRXP 5
- Target Price
- SRTS $8.00
- NRXP $31.40
- AVG Volume (30 Days)
- SRTS 88.0K
- NRXP 416.8K
- Earning Date
- SRTS 11-13-2025
- NRXP 11-13-2025
- Dividend Yield
- SRTS N/A
- NRXP N/A
- EPS Growth
- SRTS N/A
- NRXP N/A
- EPS
- SRTS N/A
- NRXP N/A
- Revenue
- SRTS $37,564,000.00
- NRXP N/A
- Revenue This Year
- SRTS N/A
- NRXP N/A
- Revenue Next Year
- SRTS $46.14
- NRXP $395.09
- P/E Ratio
- SRTS N/A
- NRXP N/A
- Revenue Growth
- SRTS 3.29
- NRXP N/A
- 52 Week Low
- SRTS $3.03
- NRXP $1.10
- 52 Week High
- SRTS $9.33
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SRTS 56.63
- NRXP 67.97
- Support Level
- SRTS $3.11
- NRXP $3.19
- Resistance Level
- SRTS $3.68
- NRXP $3.84
- Average True Range (ATR)
- SRTS 0.12
- NRXP 0.22
- MACD
- SRTS 0.09
- NRXP 0.05
- Stochastic Oscillator
- SRTS 75.32
- NRXP 70.87
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.